Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors.
- Resource Type
- journal article
- Authors
- Johansen, Maria Dinche; Urup, Thomas; Holst, Camilla Bjørnbak; Christensen, Ib Jarle; Grunnet, Kirsten; Lassen, Ulrik; Friis, Søren; Poulsen, Hans Skovgaard
- Source
- Cancer Investigation. 2018, Vol. 36 Issue 9/10, p512-519. 8p.
- Subject
- Language
- ISSN
- 0735-7907
Purpose: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.Methods: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).Results: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).Conclusions: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients. [ABSTRACT FROM AUTHOR]